296 related articles for article (PubMed ID: 17413983)
1. Mixed ovarian germ cell tumor in a BRCA2 mutation carrier.
Hamel N; Wong N; Alpert L; Galvez M; Foulkes WD
Int J Gynecol Pathol; 2007 Apr; 26(2):160-4. PubMed ID: 17413983
[TBL] [Abstract][Full Text] [Related]
2. Selective loss of heterozygosity in multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2.
Bell DW; Erban J; Sgroi DC; Haber DA
Cancer Res; 2002 May; 62(10):2741-3. PubMed ID: 12019146
[TBL] [Abstract][Full Text] [Related]
3. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma.
Lavie O; Hornreich G; Ben-Arie A; Rennert G; Cohen Y; Keidar R; Sagi S; Lahad EL; Auslander R; Beller U
Gynecol Oncol; 2004 Feb; 92(2):521-4. PubMed ID: 14766242
[TBL] [Abstract][Full Text] [Related]
4. BRCA2 germline mutation in a woman with uterine serous papillary carcinoma--case report.
Lavie O; Ben-Arie A; Pilip A; Rennert G; Cohen Y; Feiner B; Auslnader R
Gynecol Oncol; 2005 Nov; 99(2):486-8. PubMed ID: 16051327
[TBL] [Abstract][Full Text] [Related]
5. Four primary malignancies successively occurred in a BRCA2 mutation carrier: a case report.
Fruscalzo A; Damante G; Calcagno A; Di Loreto C; Marchesoni D
Cancer Invest; 2006 Oct; 24(6):611-4. PubMed ID: 16982466
[TBL] [Abstract][Full Text] [Related]
6. Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer.
Spannuth WA; Thaker PH; Sood AK
Am J Obstet Gynecol; 2007 Apr; 196(4):e6-9. PubMed ID: 17403394
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in the pathology and classification of ovarian germ cell tumors.
Roth LM; Talerman A
Int J Gynecol Pathol; 2006 Oct; 25(4):305-20. PubMed ID: 16990705
[TBL] [Abstract][Full Text] [Related]
8. Carcinosarcoma of the ovary in a patient with a germline BRCA2 mutation: evidence for monoclonal origin.
Sonoda Y; Saigo PE; Federici MG; Boyd J
Gynecol Oncol; 2000 Feb; 76(2):226-9. PubMed ID: 10637076
[TBL] [Abstract][Full Text] [Related]
9. Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes.
Machado PM; Brandão RD; Cavaco BM; Eugénio J; Bento S; Nave M; Rodrigues P; Fernandes A; Vaz F
J Clin Oncol; 2007 May; 25(15):2027-34. PubMed ID: 17513806
[TBL] [Abstract][Full Text] [Related]
10. Mixed germ cell tumor of the ovary with pure choriocarcinoma metastasis.
Fanning J; Walker RL; Shah NR
Obstet Gynecol; 1986 Sep; 68(3 Suppl):84S-85S. PubMed ID: 3016631
[TBL] [Abstract][Full Text] [Related]
11. Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.
King TA; Li W; Brogi E; Yee CJ; Gemignani ML; Olvera N; Levine DA; Norton L; Robson ME; Offit K; Borgen PI; Boyd J
Ann Surg Oncol; 2007 Sep; 14(9):2510-8. PubMed ID: 17597348
[TBL] [Abstract][Full Text] [Related]
12. Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer.
Gotlieb WH; Chetrit A; Menczer J; Hirsh-Yechezkel G; Lubin F; Friedman E; Modan B; Ben-Baruch G;
Gynecol Oncol; 2005 Jun; 97(3):780-3. PubMed ID: 15893369
[TBL] [Abstract][Full Text] [Related]
13. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
14. [The pathology of germ cell tumors of the ovary].
Ishikawa E
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 1):2479-88. PubMed ID: 6095759
[TBL] [Abstract][Full Text] [Related]
15. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.
Chetrit A; Hirsh-Yechezkel G; Ben-David Y; Lubin F; Friedman E; Sadetzki S
J Clin Oncol; 2008 Jan; 26(1):20-5. PubMed ID: 18165636
[TBL] [Abstract][Full Text] [Related]
16. The androgen receptor and genetic susceptibility to ovarian cancer: results from a case series.
Levine DA; Boyd J
Cancer Res; 2001 Feb; 61(3):908-11. PubMed ID: 11221880
[TBL] [Abstract][Full Text] [Related]
17. Hereditary breast/ovarian cancer: clinicopathological characteristics and survival of BRCA2 positive and negative cases.
Syamala V; Syamala VS; Sreeja L; Raveendran PB; Vijayalekshmi RV; Sheeja VR; Santhi S; Kuttan R; Abraham EK; Ankathil R
J Exp Ther Oncol; 2008; 7(3):227-36. PubMed ID: 19066131
[TBL] [Abstract][Full Text] [Related]
18. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
Tan DS; Rothermundt C; Thomas K; Bancroft E; Eeles R; Shanley S; Ardern-Jones A; Norman A; Kaye SB; Gore ME
J Clin Oncol; 2008 Dec; 26(34):5530-6. PubMed ID: 18955455
[TBL] [Abstract][Full Text] [Related]
19. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.
Kauff ND; Barakat RR
J Clin Oncol; 2007 Jul; 25(20):2921-7. PubMed ID: 17617523
[TBL] [Abstract][Full Text] [Related]
20. Expression of cell cycle regulatory proteins in ovaries prophylactically removed from Jewish Ashkenazi BRCA1 and BRCA2 mutation carriers: correlation with histopathology.
Kerner R; Sabo E; Gershoni-Baruch R; Beck D; Ben-Izhak O
Gynecol Oncol; 2005 Nov; 99(2):367-75. PubMed ID: 16051332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
